2007年南京市抗肿瘤药物利用分析

Analysis of antineoplastic drug application in Nanjing city during 2007

目的:评价2007年南京市抗肿瘤药物利用情况。方法:采用金额和用药频度分析法。结果:用药总金额为2.53亿元,国产药占81.46%,其中江苏恒瑞制药占12.94%,植物来源的抗肿瘤药占40%。DDDs分析中居前的以内分泌激素类为主,不含任何植物来源的抗肿瘤药、铂剂及靶向治疗药物。结论:抗肿瘤药物利用以国产药物为主,西药金额与DDDs排序不一致,原因可能是临床倾向于选择新型抗肿瘤药物,但价格昂贵限制了使用,因此相应的国内仿制药获得了良好市场。

Objective：To evaluate the application of antineoplastic drugs in Nanjing city during 2007. Methods：The application of antineoplastic drugs was analyzed based on the cost and frequency of drug use. Results：The total consumption of antineoplastic drugs was over 253 million Yuan, in which domestic drugs were over 81.46% and anti-cancer vegetable drugs were about 40%. Among all manufacturers, the highest total sum （ 12.94% ） was from Jiangsu Hengrui Pharmaceuticals. In analysis of DDDs, hormone modulators were higher, but anti-cancer vegetable drugs, platinum-containing agents and targeted drugs were far behind. Conclusion：The rank of DDDs is inconsistent with cost in all antineoplastic drugs except traditional Chinese medicine. Doctors are inclined to choose new drugs, but the price limits these drug uses. Thus, domestic drugs are becoming the first choice in cancer therapy.